FIELD: biotechnology.
SUBSTANCE: invention relates to the methods of producing a composition containing cytotoxic T-cells comprising a T-cell receptor (TCR) and a chimeric antigen receptor (CAR).
EFFECT: invention also relates to a method of increasing the proliferative capacity of antigen-specific CAR CTL-expressing CTLs, a method of increasing the transduction efficiency of antigen-specific CAR CTL-expressing CTLs, and a method of increasing the viability of antigen-specific CAR CTL-expressing CTLs.
32 cl, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | 2013 |
|
RU2729401C2 |
| CAR-T-CELLS SPECIFICALLY TARGETING CD19 ANTIGEN | 2020 |
|
RU2826298C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| SIGNAL SYSTEM | 2015 |
|
RU2731638C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2016 |
|
RU2752880C2 |
| CELL | 2015 |
|
RU2768019C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2816370C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
